In addition, our study identifies two PARP1 inhibitors, namely 3-AB and fisetin, as novel suppressors of DUX4 expression, and plausible candidates for therapeutic development for FSHD. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.